1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. p38 MAPK
  4. p38β Isoform

p38β

 

p38β Related Products (24):

Cat. No. Product Name Effect Purity
  • HY-10256
    Adezmapimod
    Inhibitor 99.96%
    Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively.
  • HY-10295
    SB 202190
    Inhibitor 99.89%
    SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively.
  • HY-10320
    Doramapimod
    Inhibitor 99.98%
    Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM.
  • HY-13241
    Ralimetinib dimesylate
    Inhibitor 99.52%
    Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively.
  • HY-10256A
    Adezmapimod hydrochloride
    Inhibitor 99.71%
    Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively.
  • HY-147518
    p38-α MAPK-IN-5
    Inhibitor
    p38-α MAPK-IN-5 (compound 4e) is a potent p38α inhibitor with IC50s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively.
  • HY-10328
    Neflamapimod
    Inhibitor 99.32%
    Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of p38α inhibitor with an IC50 for p38α of 10 nM and for p38β of 220 nM.
  • HY-10456
    TAK-715
    Inhibitor 99.89%
    TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively.
  • HY-10406
    Talmapimod
    Inhibitor 98.04%
    Talmapimod (SCIO-469) is an orally active, selective, and ATP-competitive p38α inhibitor with an IC50 of 9 nM.
  • HY-10405
    Pamapimod
    Inhibitor 99.92%
    Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively.
  • HY-108642B
    AMG-548 dihydrochloride
    Inhibitor 99.85%
    AMG-548 dihydrochloride, an orally active and selective p38α inhibitor (Ki=0.5 nM), shows slightly selective over p38β (Ki=36 nM) and >1000 fold selective against p38γ and p38δ.
  • HY-135674
    SR-318
    Inhibitor 98.87%
    SR-318 is a potent and highly selective p38 MAPK inhibitor with IC50s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively.
  • HY-14975
    R1487 Hydrochloride
    Inhibitor 98.94%
    R1487 Hydrochloride is a highly potent and selective p38α inhibitor, with Kd values of 0.2 nM and 29 nM for p38α and p38β, respectively.
  • HY-15505
    RWJ-67657
    Inhibitor 99.32%
    RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively.
  • HY-W015445
    SD-169
    Inhibitor 99.44%
    SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM.
  • HY-112182
    UM-164
    Inhibitor 98.91%
    UM-164 (DAS-DFGO-II) is a highly potent inhibitor of c-Src with a Kd of 2.7 nM.
  • HY-108645
    AL 8697
    Inhibitor 99.49%
    AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC50 of 6 nM.
  • HY-108642
    AMG-548
    Inhibitor ≥99.0%
    AMG-548, an orally active and selective p38α inhibitor (Ki=0.5 nM), shows slightly selective over p38β (Ki=36 nM) and >1000 fold selective against p38γ and p38δ.
  • HY-13241A
    Ralimetinib
    Inhibitor
    Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively.
  • HY-18862
    PF-03715455
    Inhibitor
    PF-03715455 is a potent inhaled p38 MAPK inhibitor.